Study of daily injections for Friedreich's ataxia
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests an investigational drug given as a daily injection to see if it can improve walking and balance in people with Friedreich's ataxia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test showing two abnormal copies of the FXN gene.
- You must be able to walk 25 feet in under 3 minutes (with or without a walking aid).
- You must have moderate but not severe balance and coordination problems.
- You (or a caregiver) must be able to give daily injections under the skin.
- You must not be pregnant, breastfeeding, or planning pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called DT-216P2 in people with Friedreich's ataxia. It aims to find the right dose and see how safe and tolerable it is.
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
This trial tests if a special platform that measures balance can help people with Friedreich's ataxia stand more steadily. If you have Friedreich's ataxia, can walk at least 10 metres and stand without support, you may be eligible.
This study looks at two brain chemicals (GABA and glutathione) in children and teens aged 8–15 with Friedreich's ataxia, a rare genetic condition affecting movement and coordination. The research aims to understand how these chemicals change in the brain and may help guide future treatments.
This study looks at “biomarkers” (measurable signs in the body, like test results from blood or other checks) in people with Friedreich’s ataxia. It may help researchers understand the disease better and track changes over time.
This trial tests a long-term study medication called vatiquinone for people with Friedreich's ataxia. It is designed to see if this medicine can help slow down the disease over time.
Hear when a new Friedreich Ataxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.